MASTERSWITCH
Mechanisms to Attack Steering Effectors of Rheumatoid Syndromes with Innovated Therapy Choices
| Coordinatore | ACADEMISCH ZIEKENHUIS LEIDEN
Organization address
address: Albinusdreef 2 contact info |
| Nazionalità Coordinatore | Netherlands [NL] |
| Sito del progetto | http://www.masterswitchproject.eu/ |
| Totale costo | 14˙805˙808 € |
| EC contributo | 11˙235˙980 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2007-B |
| Funding Scheme | CP-IP |
| Anno di inizio | 2008 |
| Periodo (anno-mese-giorno) | 2008-12-01 - 2013-11-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
ACADEMISCH ZIEKENHUIS LEIDEN
Organization address
address: Albinusdreef 2 contact info |
NL (LEIDEN) | coordinator | 2˙312˙612.00 |
| 2 |
KAROLINSKA INSTITUTET
Organization address
address: Nobels Vag 5 contact info |
SE (STOCKHOLM) | participant | 1˙178˙912.00 |
| 3 |
BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING
Organization address
address: Al. Fleming Street 34 contact info |
EL (VARI-ATHENS) | participant | 944˙480.00 |
| 4 |
MEDIZINISCHE UNIVERSITAET WIEN
Organization address
address: SPITALGASSE 23 contact info |
AT (WIEN) | participant | 806˙200.00 |
| 5 |
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Organization address
address: Rue Michel -Ange 3 contact info |
FR (PARIS) | participant | 695˙000.00 |
| 6 |
UNIVERSITAET ZUERICH
Organization address
address: Raemistrasse 71 contact info |
CH (ZURICH) | participant | 675˙000.00 |
| 7 |
UNIVERSITY OF LEEDS
Organization address
address: WOODHOUSE LANE contact info |
UK (LEEDS) | participant | 607˙705.20 |
| 8 |
FRIEDRICH-ALEXANDER-UNIVERSITAT ERLANGEN NURNBERG
Organization address
address: SCHLOSSPLATZ 4 contact info |
DE (ERLANGEN) | participant | 501˙444.00 |
| 9 |
UNIVERSITAET ZU KOELN
Organization address
address: ALBERTUS MAGNUS PLATZ contact info |
DE (KOELN) | participant | 500˙000.00 |
| 10 |
UNIVERSITY OF GLASGOW
Organization address
address: University Avenue contact info |
UK (GLASGOW) | participant | 423˙828.00 |
| 11 |
AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
Organization address
address: CALLE SERRANO 117 contact info |
ES (MADRID) | participant | 415˙512.00 |
| 12 |
BIOMEDCODE ELLAS ANONIMI ETERIA EPISTIMONIKIS KAI TEXNOLOGIKIS EREVNASKAI EMBORIKIS EKMETALLEFSIS EPHARMOGON IATRIKIS
Organization address
address: ALEXANDER FLEMING STREET 34 contact info |
EL (VARI) | participant | 412˙500.00 |
| 13 |
MaimoniDex (UK) Ltd
Organization address
address: "ONE LONDON WALL, 6TH FLOOR" contact info |
UK (LONDON) | participant | 412˙500.00 |
| 14 |
HYBRIGENICS SA
Organization address
address: IMPASSE REILLE 3-5 contact info |
FR (PARIS) | participant | 411˙527.00 |
| 15 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Organization address
address: University Offices, Wellington Square contact info |
UK (OXFORD) | participant | 225˙000.00 |
| 16 |
CRANFIELD UNIVERSITY
Organization address
address: College Road contact info |
UK (CRANFIELD - BEDFORDSHIRE) | participant | 210˙000.80 |
| 17 |
IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE
Organization address
address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD contact info |
UK (LONDON) | participant | 170˙010.00 |
| 18 |
Redoxis AB
Organization address
address: MEDICINAREGATAN 8A SAHLGRENSKA SCIENCE PARK contact info |
SE (GOTEBORG) | participant | 150˙000.00 |
| 19 |
KING'S COLLEGE LONDON
Organization address
address: Strand contact info |
UK (LONDON) | participant | 121˙874.64 |
| 20 |
UNIVERSITY OF SUSSEX
Organization address
address: Sussex House contact info |
UK (FALMER, BRIGHTON) | participant | 61˙874.40 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Objective: To delineate the biological and molecular pathways that initiate and drive chronic inflammatory disease and to transform the knowledge obtained into the development of novel anti-inflammatory interventions. Focus will be given to Rheumatoid Arthritis (RA) since longitudinal data indicate that intensive treatment can prevent persistency and chronicity. State of the Art and beyond: The first generation of targeted therapies in chronic inflammatory disease used RA as prototype disease for clinical development. These therapies are now also used in other inflammatory disorders. Although treatments have been developed that are effective in a proportion of patients, they are aspecific, relatively toxic and do not mediate cure. Currently, it is unknown which molecular effects need to be induced and/or targeted to prevent induction or persistency of RA. However, this is within reach through a strong international consortium of world-leading European groups that cover both basic- and translational research. Work plan: The general strategy for the project is to enable parallel studies that are focussed on critical switch moments in the biological processes that drive chronicity of inflammation. As the consortium consists of a multidisciplinary team with basic- and clinical expertise, translational research will be conducted to delineate the molecular basis of dysregulated inflammation, the RA-specific autoimmune-response and organ specific pathobiology. The final aim is to develop novel- and specific anti-inflammatory therapies. Impact of the project: This project will (i) identify the molecular networks underlying chronic inflammation and thereby (ii) will define novel targets for drug-development as well as (iii) algorithms that will predict outcome of therapy. Moreover, within this project European SMEs will evaluate new interventions (iv) and this project will (v) offer a platform to rapidly develop ideas and patents into new therapies.'
Introduzione (Teaser)
Chronic joint inflammatory diseases like rheumatoid arthritis (RA) are incurable but early diagnosis and therapy can alleviate symptoms. EU-funded researchers studied RA initiation and progression for early diagnosis and effective therapy.